Melanoma vaccine trial success raises questions on broader cancer vaccine efficacy

A late-stage melanoma vaccine trial succeeded, but divergent results across other cancer vaccine trials have the field questioning whether mRNA platforms will translate broadly. The success is confirmed for melanoma, but uncertainty remains on generalizability to other cancers and on the durability of response.